Eloralintide
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Eli Lilly · Phase 2 · Active, not recruiting · Enrollment 200
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Macupatide (Macupatide + Eloralintide Placebo) | Obesity + T2D | n/r | n/r | n/r | n/r |
| Eloralintide (Elorlintide + Macupatide Placebo) | Obesity + T2D | n/r | n/r | n/r | n/r |
| Macupatide + Eloralintide | Obesity + T2D | n/r | n/r | n/r | n/r |
| Placebo (Macupatide Placebo + Elorlintide Placebo) | Obesity + T2D | n/r | n/r | n/r | n/r |